PPARA and metabolic dysfunction-associated steatohepatitis: From recent Inventiva’s press release regarding the Phase IIb NATIVE clinical trial in NASH patients, the pan-PPAR agonist Lanifibranor meets a statistically significant decrease (p = 0.004) in at least two points in the SAF activity score (combining hepatocellular inflammation and ballooning), compared to baseline, with no worsening of fibrosis at the dose of 1,200 mg/day (49% in Lanifibranor arm versus 27% in the placebo arm) after 24 weeks of treatment.